<?xml version='1.0' encoding='utf-8'?>
<document id="24858641"><sentence text="Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine."><entity charOffset="60-69" id="DDI-PubMed.24858641.s1.e0" text="maraviroc" /><entity charOffset="71-82" id="DDI-PubMed.24858641.s1.e1" text="raltegravir" /><entity charOffset="84-94" id="DDI-PubMed.24858641.s1.e2" text="etravirine" /><pair ddi="false" e1="DDI-PubMed.24858641.s1.e0" e2="DDI-PubMed.24858641.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24858641.s1.e0" e2="DDI-PubMed.24858641.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24858641.s1.e0" e2="DDI-PubMed.24858641.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24858641.s1.e1" e2="DDI-PubMed.24858641.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24858641.s1.e1" e2="DDI-PubMed.24858641.s1.e2" /></sentence><sentence text="Aim of this study was to report the 204-week efficacy and safety results of a novel PI- and NRTI-sparing regimen for salvage therapy including maraviroc, raltegravir, etravirine in 28 failing HIV-infected patients with R5-tropic virus"><entity charOffset="143-152" id="DDI-PubMed.24858641.s2.e0" text="maraviroc" /><entity charOffset="154-165" id="DDI-PubMed.24858641.s2.e1" text="raltegravir" /><entity charOffset="167-177" id="DDI-PubMed.24858641.s2.e2" text="etravirine" /><pair ddi="false" e1="DDI-PubMed.24858641.s2.e0" e2="DDI-PubMed.24858641.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24858641.s2.e0" e2="DDI-PubMed.24858641.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24858641.s2.e0" e2="DDI-PubMed.24858641.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24858641.s2.e1" e2="DDI-PubMed.24858641.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24858641.s2.e1" e2="DDI-PubMed.24858641.s2.e2" /></sentence><sentence text=" The trend of laboratory parameters was tested by ANOVA for repeated measures and Greenhouse-Geisser probabilities were reported" /><sentence text=" Results were described as median (Q1-Q3) values" /><sentence text=" Twenty-six (93%) out of 28 patients completed 204 weeks of treatment" /><sentence text=" Virological success (HIV-RNA&lt;50 copies/mL) at week 204 was 96%" /><sentence text=" CD4+ counts significantly increased [244 (158-213) cells/mm3, p&lt;0" /><sentence text="0001] from baseline [247 (68-355) cells/mm(3)] as well as CD4+ percentage" /><sentence text=" Four serious adverse events (1 death due to Hodgkins's lymphoma, 1 anal cancer, 1 Hodgkins's lymphoma, 1 recurrence of mycobacterial spondylodiscitis) were observed; three events led to transitory discontinuation of the antiretroviral therapy due to drug-drug interaction" /><sentence text=" BMI (p&lt;0" /><sentence text="0001) and waist circumference (p&lt;0" /><sentence text="0001) significantly increased over 204 weeks" /><sentence text=" An amelioration was also observed in relation to haemoglobin (p=0" /><sentence text="0006), platelets (p&lt;0" /><sentence text="0001), white blood cell (p=0" /><sentence text="013), neutrophils (p=0" /><sentence text="301), lymphocytes (p=0" /><sentence text="207) and creatinine (p&lt;0"><entity charOffset="9-19" id="DDI-PubMed.24858641.s18.e0" text="creatinine" /></sentence><sentence text="0001)" /><sentence text=" In highly treatment-experienced patients the maraviroc, raltegravir and etravirine combination is associated with a good long-term efficacy and safety profile"><entity charOffset="46-55" id="DDI-PubMed.24858641.s20.e0" text="maraviroc" /><entity charOffset="57-68" id="DDI-PubMed.24858641.s20.e1" text="raltegravir" /><entity charOffset="73-83" id="DDI-PubMed.24858641.s20.e2" text="etravirine" /><pair ddi="false" e1="DDI-PubMed.24858641.s20.e0" e2="DDI-PubMed.24858641.s20.e0" /><pair ddi="false" e1="DDI-PubMed.24858641.s20.e0" e2="DDI-PubMed.24858641.s20.e1" /><pair ddi="false" e1="DDI-PubMed.24858641.s20.e0" e2="DDI-PubMed.24858641.s20.e2" /><pair ddi="false" e1="DDI-PubMed.24858641.s20.e1" e2="DDI-PubMed.24858641.s20.e1" /><pair ddi="false" e1="DDI-PubMed.24858641.s20.e1" e2="DDI-PubMed.24858641.s20.e2" /></sentence><sentence text="" /></document>